Biogen Inc. (BIIB)

Common-Size Income Statement
Quarterly Data

Difficulty: Beginner

Biogen Inc., common-size consolidated income statement (quarterly data)

	3 months ended	Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Product, net
	Revenues from anti-CD20 therapeutic programs
	Other
	Revenues
	Cost of sales, excluding amortization and impairment of acquired intangible assets
	Gross profit
	Research and development
	Selling, general and administrative
	Amortization and impairment of acquired intangible assets
	Collaboration (profit) loss sharing
	Loss on assets and liabilities held for sale
	Gain (loss) on fair value remeasurement of contingent consideration
	Restructuring charges
	Acquired in-process research and development
	TECFIDERA litigation settlement and license charges
	Gain on sale of rights
	Income from operations
	Other income (expense), net
	Income before income tax expense and equity in loss of investee, net of tax
	Income tax expense
	Equity in loss of investee, net of tax
	Net income
	Net (income) loss attributable to noncontrolling interests, net of tax
	Net income attributable to Biogen Inc.

Income statement item	Description	The company
Income from operations	The net result for the period of deducting operating expenses from operating revenues.	Biogen Inc.’s income from operations as a percentage of revenues increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Income before income tax expense and equity in loss of investee, net of tax	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Biogen Inc.’s income before income tax expense and equity in loss of investee, net of tax as a percentage of revenues increased from Q4 2018 to Q1 2019 but then slightly declined from Q1 2019 to Q2 2019.
Net income attributable to Biogen Inc.	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Biogen Inc.’s net income attributable to Biogen Inc. as a percentage of revenues increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.

	Biogen Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality